AttendMe Owl Logo
AttendMe
Evidence Evolution
ENT / Head & Neck SurgeryENT / Head & Neck Surgery

How This Evidence Evolved

Sudden Hearing Loss Steroid Treatment

From no standard treatment to oral steroids, intratympanic salvage, and combination therapy

29.3

Timeline

Signal

Early observations and pilot data that first suggested a new direction

The 2019 AAO-HNS guideline reports that sudden sensorineural hearing loss affects 5–27 per 100,000 people annually and emphasizes prompt recognition and management. Wilson 1980 described double-blind studies of oral steroids, defining sudden loss as at least 30 dB over three contiguous frequencies in three days or less. Follow-up audiograms were obtained at four weeks and three months. Steroids significantly improved hearing recovery in patients with moderate loss. The authors proposed viral cochleitis as a possible cause; the abstract does not establish the specific trial size or prednisone regimen.
Proof

Landmark RCTs and pivotal trials that established the evidence base

The Rauch trial, published in JAMA in 2011, compared oral and intratympanic steroids as primary therapy for ISSNHL. This noninferiority trial at 16 otology practices randomized 250 patients presenting within 14 days of onset to oral prednisone (60 mg/day for 14 days with a 5-day taper) or 4 intratympanic injections of methylprednisolone 40 mg/mL over 14 days. At 2 months, PTA improved by 30.7 dB with oral and 28.7 dB with intratympanic treatment; the 2.0-dB difference (upper confidence limit 6.6 dB) was within the 10-dB noninferiority margin. This supported intratympanic injection as an alternative primary route. The trial had no untreated arm, and the Battaglia combination-therapy report cites untreated ISSNHL recovery of 32–65%, so spontaneous recovery confounds outcome assessment in this condition.
Extension

Follow-up studies, subgroup analyses, and real-world validation

Subsequent research focused on intratympanic steroids as salvage therapy for patients who fail initial oral steroid treatment. In a randomized salvage trial (Ho 2004) in severe or profound loss that had not improved after 10 days of oral steroids, weekly intratympanic dexamethasone for 3 weeks gave >30-dB recovery in 8 of 15 (53.3%) vs 1 of 14 (7.1%) controls (mean gain 28.4 vs 13.2 dB, P<.05). A 2015 meta-analysis by Crane and colleagues pooled 6 salvage RCTs (283 subjects): odds ratio 6.04 (95% CI 3.26-11.2), with the caution that the trials were of poor quality. Combination therapy (simultaneous oral plus intratympanic steroids) gave mixed results — in Battaglia 2008 (51 patients), adding intratympanic dexamethasone to a high-dose prednisone taper raised the proportion with >15-dB PTA gain (p<0.02), while in the quasirandomized Koltsidopoulos 2013 trial (92 patients), recovery was 67.39% vs 52.17%, with no significant difference in hearing gain (p=0.10). The 2019 AAO-HNS guideline lists hyperbaric oxygen with steroids as an option within 2 weeks of onset, or as salvage within 1 month.
Guidelines

Integration into clinical practice guidelines and recommendations

The 2019 AAO-HNS guideline makes initial corticosteroids within two weeks an option, not a strong recommendation. It recommends intratympanic steroid salvage for incomplete recovery two to six weeks after onset, prompt audiometry within 14 days, and MRI or auditory brainstem response to evaluate retrocochlear pathology.
AAO-HNS

Corticosteroids may be offered as initial therapy within 2 weeks of symptom onset (Option, KAS 8); offer, or refer for, intratympanic steroid therapy when recovery is incomplete 2 to 6 weeks after onset (Recommendation, KAS 10); evaluate for retrocochlear pathology with MRI or auditory brainstem response (Recommendation, KAS 6)

Now

Current standard of care and ongoing research directions

The Rauch 2011 report notes more than 30 years of oral-steroid use; its trial compared two routes without an untreated arm. The 2019 AAO-HNS guideline makes initial corticosteroids an option and requires discussion of evidence limitations. Wilson 1980 reported benefit in moderate hearing loss. Crane 2015 pooled three placebo-controlled trials with 181 subjects: steroids did not significantly outperform placebo (OR 1.52, 95% CI 0.83–2.77). Battaglia combination-therapy cites untreated recovery of 32–65%, highlighting the need to distinguish treatment effects from natural recovery. The guideline recommends against routine antivirals, thrombolytics, vasodilators or vasoactive substances.

Landmark Trials in This Story

Wilson 19801980Landmark

The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study

Hearing recovery

Archives of otolaryngology (Chicago, Ill. : 1960)Double-blind clinical study of oral steroids
Rauch 20112011Landmark

Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial

Change in pure tone average at 2 months

JAMARCT (non-inferiority)N=250
Battaglia combination therapy2008

Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss

PTA gain >15 dB at 4 weeks after the last injection: IT dexamethasone plus high-dose prednisone taper vs taper alone (higher proportion with combination, p<0.02)

Otology & neurotologyRCTN=51
Crane 20152015

Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials.

Hearing recovery with salvage steroids after failed traditional therapy (6 RCTs, 283 subjects): salvage steroids vs control (odds ratio 6.04, 95% CI 3.26-11.2; poor-quality trials); steroid vs placebo, odds ratio 1.52 (95% CI 0.83-2.77)

LaryngoscopeMeta-analysis of randomized controlled trials (15 articles)N=1,166
Ho 20042004

Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment.

Hearing gain >30 dB at a minimum 1-month follow-up in oral-steroid non-responders: weekly IT dexamethasone for 3 weeks vs control 8/15 (53.3%) vs 1/14 (7.1%); mean gain 28.4 vs 13.2 dB (P<.05)

LaryngoscopeRandomized controlled trialN=29
Koltsidopoulos 20132013

Intratympanic and systemic steroids for sudden hearing loss.

Significant hearing recovery 3 months after treatment: systemic prednisolone plus 3 IT dexamethasone injections vs prednisolone alone 31/46 (67.39%) vs 24/46 (52.17%); median PTA gain 23.12 vs 16.87 dB (between-group differences not significant, p=0.10 and p=0.13)

Otol NeurotolProspective, quasirandomized, multicenter clinical trialN=92

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

How quickly should steroids be started for sudden hearing loss?+
If corticosteroids are offered, timing matters. The 2019 AAO-HNS guideline asks for audiometry within 14 days of symptom onset and offers corticosteroids as an option within 2 weeks of onset. For incomplete recovery, it recommends intratympanic steroids 2 to 6 weeks after onset, and lists hyperbaric oxygen with steroids as a salvage option within 1 month of onset.
When should intratympanic steroid salvage be offered?+
Offer, or refer for, intratympanic steroid therapy when recovery is incomplete 2 to 6 weeks after onset (AAO-HNS 2019, Recommendation). Protocols vary: in Ho 2004, salvage dexamethasone was injected weekly for 3 weeks; in the Rauch trial (primary therapy), methylprednisolone 40 mg/mL was given as 4 doses over 14 days. In Ho 2004, 53.3% of oral-steroid non-responders recovered >30 dB with intratympanic dexamethasone vs 7.1% of controls.
What workup is needed for sudden sensorineural hearing loss?+
The AAO-HNS guideline recommends audiometry as soon as possible, within 14 days, and MRI or auditory brainstem response for retrocochlear pathology. The guideline recommends against routine head CT and routine laboratory testing; testing should address specific clinical indications.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026